M.D. Anderson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).
M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.
M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.
Top-decile sponsor footprint
M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,692 total, page 11 of 54
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
NCT02754544
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
NCT05136807
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
NCT02710253
Personalized NK Cell Therapy in CBT
NCT02727803
Couple-Based Meditation for Metastatic Lung Cancer Patients and Their Partners
NCT02596490
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
NCT02726750
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
NCT03039439
Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients
NCT03048266
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
NCT02392572
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
NCT02464696
Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma
NCT04778449
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
NCT02479698
Compassionate Access of the Miltenyi Device for CD34+ Cell Selection
NCT02438904
Measuring Surgical Recovery After Radical Cystectomy
NCT03193970
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
NCT02361320
Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma
NCT02106988
Prospective Study of Colon Serrated Polyps
NCT02332785
PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing
NCT02282969
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
NCT02115295
Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer
NCT02107105
Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix
NCT04723095
Quality of Life and Function of Patients With Pelvic Tumors After Undergoing Hemipelvectomy
NCT05134142
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
NCT01608152
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
NCT01746836
Domperidone in Treating Patients With Gastrointestinal Disorders
NCT01696734
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
NCT03458676
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
NCT01624805
Molecular Basis for Variations in Hereditary Colorectal Cancer Syndromes
NCT02863172
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
NCT01772771
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
NCT01515527
Long-Term Follow-Up of Recipient of Gene Transfer Research
NCT01492036
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
NCT01409161
Comprehensive Data Collection and Follow-Up for Patients With Thyroid, Parathyroid and Adrenal Disease
NCT03050762
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
NCT01371630
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
NCT01365169
Wide-Field and High Resolution In Vivo Imaging in Visualizing Lesions in Patients With Oral Neoplasia Undergoing Surgery
NCT01269190
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
NCT00501826
PROSPECT - Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification
NCT05049837
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
NCT00477100
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
NCT00801489
Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors
NCT00488878
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
NCT00493688
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
NCT00816114
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
NCT00991094
The Collection and Storage of Umbilical Cord Blood for Transplantation
NCT01728545
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
NCT00412594
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
NCT00539162
Psychophysical Studies of Cancer Therapy Pain
NCT00515060
New Assessment System in Measuring Symptom Distress in Cancer Patients
NCT00505245
Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
NCT07407920
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 748 |
| Phase 2 | 971 |
| Phase 3 | 96 |
| Phase 4 | 28 |
Therapeutic Areas
What is open in the M.D. Anderson Cancer Center pipeline
549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).
Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).
Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.